Research and Clinical Trials
Penn Community Practice at Penn Presbyterian
Medical Center have conducted numerous research
studies focused on the treatment and clinical
outcomes of chronic viral hepatitis infection,
especially in the HIV population. Recent studies
- The incidence and risks factors
for weight loss during dual HIV and hepatitis
C virus therapy.
- Measurement of adherence
to pegylated interferon and ribavirin hepatitis
- The prevalence, risk factors,
and clinical significance of occult hepatitis
B virus infection in HIV-infected patients.
Active research is focused on elucidating additional
risk factors for end-stage liver disease among
HIV/hepatitis C-coinfected patients.
Penn Community Practices at Penn Presbyterian
Medical Center participate are active in the
following clinical trial:
Efficacy of Nitazoxanide Plus Peginterferon
Alfa-2a and Ribavirin in Chronic Hepatitis
C Treatment-Naïve Genotype 1 Subjects
with HIV Coinfection (not yet available): This
clinical trial will examine the addition of
nitazoxanide to the current standard of care
of 48 weeks of pegylated interferon and ribavirin
among HIV and hepatitis C genotype 1-coinfected
patients who have not received prior therapy
for hepatitis C. Nitazoxanide is currently
approved by the U.S. Food and Drug Administration
(FDA) for the treatment of parasitic infections.
The addition of this medication has been associated
with improved hepatitis C treatment responses
in clinical trials performed in hepatitis C-infected
patients without HIV.